N

Neuren Pharmaceuticals
NEU

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
A$1.45B
EV
A$1.23B
Shares Outstanding
125.86M
Beta
1.85

Wall Street View

Analyst Rating
BUY
Analyst Target Price
A$24.97
P/E 2025E
66.22x
P/Revenue 2025E
21.66x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Neuren Pharmaceuticals Limited

gainify

N

Neuren Pharmaceuticals Limited

NEU

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of a...

Sector

Healthcare

Industry

Biotechnology

CEO

Pilcher, Jonathan

Employees

8

IPO Date

2005-02-01

Headquarters

697 Burke Road, Suite 201, Camberwell, Victoria, 3124, Australia

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved